AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Similar levels of HIV-DNA and residual viremia are found in virologically suppressed individuals who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to EVG/COBI/FTC enrolled in the Be-OnE StudyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Role of analytical treatment interruption on HIV peripheral reservoir diversificationView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Detection in HIV proviral DNA of drug resistance mutations in patients with low permanent viral loadsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutationsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to IbalizumabView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 StudyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Evaluation of HIV-1 tropism in multidrug-resistant cART failing patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Short- and long-term direct medical costs of late and very late HIV presentationView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M StudyView Abstract
